We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

85 hedge funds and large institutions have $248M invested in AEON Biopharma in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

12% more capital invested

Capital invested by funds: $222M → $248M (+$26.3M)

5% more funds holding

Funds holding: 81 → 85 (+4)

0.07% more ownership

Funds ownership: 1.17% → 1.24% (+0.07%)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

Holders
85
Holders Change
+4
Holders Change %
+4.94%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
13
Reduced
16
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIM
Cowen Investment Management
New York
+$5.72M
2
WCMNY
Westchester Capital Management (New York)
New York
+$5.5M
3
MC
Meteora Capital
Florida
+$5.26M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.87M
5
DFCM
Dark Forest Capital Management
Puerto Rico
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.68M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.12M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$3.87M
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.43M
5
Calamos Advisors
Calamos Advisors
Illinois
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$3.66M -$2.16M -3,018 -37%
DFCM
27
Dark Forest Capital Management
Puerto Rico
$3.65M +$3.01M +4,202 +495%
QL
28
Quarry LP
New York
$3.1M +$3.07M +4,289 New
WA
29
Whitebox Advisors
Minnesota
$3.03M – – –
State of Wisconsin Investment Board
30
State of Wisconsin Investment Board
Wisconsin
$2.89M – – –
Goldman Sachs
31
Goldman Sachs
New York
$2.79M – – –
KL
32
KIM LLC
Kansas
$2.51M – – –
HIM
33
HGC Investment Management
Ontario, Canada
$2.51M +$2.49M +3,472 New
ETH
34
Exos TFP Holdings
New York
$2.42M +$2.39M +3,339 New
CCA
35
Castle Creek Arbitrage
Colorado
$2.4M -$166K -232 -7%
MTCM
36
Mint Tower Capital Management
Netherlands
$2.35M +$1.37M +1,907 +142%
GCL
37
Glazer Capital LLC
New York
$2.32M +$50.9K +71 +2%
Nomura Holdings
38
Nomura Holdings
Japan
$2.26M – – –
Janus Henderson Group
39
Janus Henderson Group
United Kingdom
$2.25M -$1.37M -1,919 -38%
Balyasny Asset Management
40
Balyasny Asset Management
Illinois
$2.25M – – –
BFM
41
Boothbay Fund Management
New York
$1.94M +$1.69M +2,364 +758%
CSS
42
Cubist Systematic Strategies
Connecticut
$1.93M -$349K -487 -15%
Citadel Advisors
43
Citadel Advisors
Florida
$1.89M -$4.12M -5,752 -69%
FCM
44
Farallon Capital Management
California
$1.51M – – –
DCM
45
Dupont Capital Management
Delaware
$1.51M – – –
RCM
46
Rivernorth Capital Management
Florida
$1.41M +$995K +1,388 +250%
WRBC
47
W.R. Berkley Corp
Connecticut
$1.23M – – –
MCM
48
Moore Capital Management
New York
$1.01M – – –
CL
49
CSS LLC
Illinois
$1M -$246K -344 -20%
AC
50
Athos Capital
Hong Kong
$898K – – –
1
2
3 4

AEON Hedge Fund Activity: Q4 2022 in Review

85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2022, worth a combined $248M — up 12% from $222M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 8 closed out — a net gain of 5 holders — while 13 added to existing stakes and 16 trimmed.

The largest buyer was Cowen Investment Management, opening a new position worth an estimated $5.72M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.68M sold.

  • 85 institutional investors held AEON Biopharma (AEON) as of Q4 2022, up from 81 in Q3 2022.
  • Funds reported $248M of AEON Biopharma stock for Q4 2022, up 12% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q4 2022 and 8 closed out, a net change of +5 holders.
  • The largest AEON Biopharma buyer in Q4 2022 was Cowen Investment Management, an estimated $5.72M added.
  • The largest AEON Biopharma seller in Q4 2022 was UBS O'Connor, an estimated $4.68M sold.

Based on aggregated 13F filings for Q4 2022.